/
Oncology
Advanced Breast Cancer
65
Pipeline Programs↗
38
Active Trials↗
27
Companies Involved↗
Advanced Breast Cancer is a moderately active landscape with 65 programs across 27 companies. The most active players are AstraZeneca, Shanghai Hengrui Pharmaceutical Co., Ltd., BriaCell Therapeutics Corporation. 17 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 123
Phase 222
Phase 317
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
44 of 53 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 53 classified programs, each share of the total. Modality classified for 85% of 65 pipeline programs.
Analysis
Trial Status
43
clinical trials
Recruiting22 · 51%
Active, not recruiting11 · 26%
Completed5 · 12%
Not yet recruiting5 · 12%
Clinical Trials
Trial Activity
43 trials
A Multicenter, Single-arm, Phase II Clinical Study of Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07810088·40 enrolled
Efficacy and Safety of Capecitabine and Cyclophosphamide (XC) Versus Physician's Choice as Maintenance Therapy for Advanced Breast Cancer: a Randomized, Controlled, Open-label Clinical Trial
Recruiting·—·Preclinical·NCT05876065·86 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)